Skip to content
ppharmaranks
Menu
Class IIOngoing

Wegovy (semaglutide) Injection recall

FDA recall D-0245-2026 · initiated Dec 19, 2025

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Jan 7, 2026How we research

Novo Nordisk Inc. recalled Wegovy (semaglutide) Injection in Dec 2025 — an FDA Class II recall (D-0245-2026) because Presence of Particulate Matter: Hair was found in a prefilled syringe.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Presence of Particulate Matter: Hair was found in a prefilled syringe

Something got into the product

A physical or chemical contaminant was found — glass or metal fragments, or a solvent that should not be there.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot #: RZFYK06, RZFYA53; Exp Date 3/31/2027

Quantity recalled: N/A

Details

Product
Wegovy (semaglutide) Injection, 1 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark, Product of Denmark, Novo Nordisk A/S, Novo Nordisk Inc., Plainsboro, NJ 08536, NDC 0169-4501-14
Recalling company
Novo Nordisk
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide within the United States.
Initiated
Dec 19, 2025
FDA report date
Jan 7, 2026
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Wegovy (semaglutide) Injection recalled?
Novo Nordisk Inc. recalled Wegovy (semaglutide) Injection in Dec 2025 — an FDA Class II recall (D-0245-2026) because Presence of Particulate Matter: Hair was found in a prefilled syringe. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Wegovy (semaglutide) Injection recalled?
Per the FDA enforcement record, the reason for recall D-0245-2026 was: Presence of Particulate Matter: Hair was found in a prefilled syringe
Is a recalled Wegovy (semaglutide) Injection dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Wegovy (semaglutide) Injection are affected?
Distributed: Nationwide within the United States.. The recall covers these lots — Lot #: RZFYK06, RZFYA53; Exp Date 3/31/2027. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0245-2026.

Source: openFDA Drug Enforcement record D-0245-2026

← All drug recalls